Abstract 2328P
Background
A subset of cancers display distinctive phenotypes and harbor pathognomonic genetic alterations. Breast invasive lobular carcinoma (ILC), the most common special histologic subtype of breast cancer (BC), has a distinctive discohesive phenotype, caused by bi-allelic inactivation of CDH1 (E-cadherin), representing a strong genotypic-phenotypic correlation. Here, we sought to apply an artificial intelligence (AI)-based model trained to detect CDH1 bi-allelic mutations (i.e. inactivating mutation and loss of heterozygosity (LOH)) using H&E-stained whole slides images (WSI) as input to identify ILCs with alternative mechanisms of CDH1 inactivation.
Methods
We applied the AI-model trained to detect CDH1 biallelic mutations using WSIs to a cohort of 1,057 BCs with available targeted sequencing data. To determine the molecular underpinning of cases predicted to harbor CDH1 bi-allelic mutations but lacking these genetic alterations by targeted sequencing, we conducted the re-analysis of targeted sequencing data, CDH1 gene promoter methylation assessment and/or whole genome sequencing (WGS) analysis.
Results
We identified 34 cases predicted by the AI-model to harbor a CDH1 bi-allelic mutations that lacked these alterations by targeted sequencing. Reanalysis of targeted sequencing data and/or promoter methylation assessment revealed CDH1 promoter methylation (n=20), CDH1 homozygous deletions (n=3) and CDH1 intragenic deletion associated with LOH (n=1) in these cases. In addition, WGS of an ILC revealed a translocation t(13;16) predicted to result in a novel deleterious fusion gene affecting CDH1 with loss of exons 1-2 and the regulatory regions of this gene, associated with LOH. By applying a genomics-driven AI model we detected alternative mechanisms of CDH1 inactivation in 25/34 (74%) cases.
Conclusions
In the context of genotypic-phenotypic correlations, AI-based methods trained on a genetic ground truth can result in the identification of alternative/convergent molecular mechanisms underpinning histologic entities. This study highlights the potential of combinatorial approaches integrating deep learning methods and genomics in pathology.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Breast Cancer Research Foundation, National Institutes of Health (NIH)/National Cancer Institute.
Disclosure
Y.K. Wang, J. Bernhard, J. Sue, M.C.H. Lee, R. Godrich, A. Casson, J.D. Kunz, B. Rothrock, G.J. Oakley, D. Klimstra, T. Fuchs: Financial Interests, Personal, Stocks/Shares: Paige; Financial Interests, Personal, Full or part-time Employment: Paige. B. Weigelt: Financial Interests, Personal, Research Funding: Repare Therapeutics. C. Kanan: Financial Interests, Personal, Stocks/Shares, Also Consultant: Paige. J.S. Reis-Filho: Financial Interests, Personal, Other, Consultant: Goldman Sachs, Eli Lilly, Saga Diagnostics; Financial Interests, Personal, Other, Member of the Scientific Advisory Board and Consultant: Repare Therapeutics, Paige.AI; Financial Interests, Personal, Advisory Board: Personalis, Roche Tissue Diagnostics; Financial Interests, Personal, Advisory Board, Member of the Scientific Advisory Board: Bain Capital; Financial Interests, Personal, Advisory Board, Ad hoc member of the Pathology Scientific Advisory Board: Daiichi Sankyo, Merck; Financial Interests, Personal, Advisory Board, Ad hoc member of the Oncology Scientific Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board, Member of the SAB: MultiplexDX; Financial Interests, Personal, Member of Board of Directors: Odyssey Bio, Grupo Oncoclinicas; Financial Interests, Personal, Stocks/Shares: Repare Therapeutics; Financial Interests, Personal, Other, Stock options: Paige.AI. All other authors have declared no conflicts of interest.
Resources from the same session
2325P - Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
Presenter: Rafael Rosell
Session: Poster session 16
2326P - Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy
Presenter: Michele Ghidini
Session: Poster session 16
2327P - The impact of the microenvironment on the intratumoral cellular heterogeneity in colorectal cancer
Presenter: Idan Carmi
Session: Poster session 16
2329P - Evidence for the utility of artificial intelligence and image analysis in Ki-67 quantification in solid tumors
Presenter: Xavier Pichon
Session: Poster session 16
2331P - Interest of next generation sequencing (NGS) for integrated molecular diagnosis of HER2-low breast cancer
Presenter: Jean Louis Merlin
Session: Poster session 16
2332P - Overall survival in breast cancer patients with HER2-low status single- center experience
Presenter: Joanna Huszno
Session: Poster session 16
2333P - Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancers
Presenter: Anna Karlsson
Session: Poster session 16
2334P - Pathologic patterns following different neoadjuvant therapies in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster session 16
2335P - Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma
Presenter: Jianfu Li
Session: Poster session 16